[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Osaka University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100655988","a-multicenter-prospective-observational-study-of-acute-ischemic-stroke-in-patients-with-active-cancer-100655988",false,"NCT07819526","Acute Ischemic Stroke in Patients With Active Cancer","Clinical Characteristics and Stroke Recurrence in Patients With Acute Ischemic Stroke and Active Cancer: The CAT-AIS Multicenter Prospective Observational Study","CAT-AIS","Inclusion Criteria:\n\n1. Acute ischemic stroke diagnosed within 7 days after symptom onset or the time last known well.\n2. Active cancer at the time of the index stroke, as defined below.\n\nExclusion Criteria:\n\n1. The patient or a legally acceptable representative indicates that the patient does not wish to participate.\n2. The investigator considers enrolment inappropriate.","ALL",{"count":19,"type":20},500,"ESTIMATED","3 Months","OBSERVATIONAL","The goal of this multicenter prospective observational study, conducted at 24 hospitals in Japan, is to learn about recurrent ischemic stroke in people with active cancer who develop acute ischemic stroke. One of the main objectives is to evaluate how often ischemic stroke recurs during follow-up.\n\nThe main questions this study aims to answer are:\n\n* How often does ischemic stroke recur within 3 months after the initial stroke?\n* Which clinical factors may be associated with recurrent ischemic stroke?\n* What other clinical outcomes occur during follow-up?\n\nParticipants will receive medical care determined by their treating physicians. Researchers will collect information about participants' cancer, stroke characteristics, test results, treatments, recurrent ischemic stroke, and other clinical outcomes. Researchers will also explore whether clinical factors are associated with recurrent ischemic stroke and other outcomes. This study will not assign participants to a specific treatment.",[25,26],"Acute Ischemic Stroke","Active Cancer",[28,29,30,31],"Cancer-associated ischemic stroke","Recurrent ischemic stroke","Cancer","Antithrombotic therapy","RECRUITING","2026-09-16",{"date":35,"type":36},"2026-09-21","ACTUAL",{"date":38,"type":36},"2026-03-01",{"date":40,"type":20},"2032-03-31",{"name":42,"class":43},"Osaka University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100587112","isolated-surgical-aortic-valve-replacement-in-low-risk-as-patients-100587112","NCT06924151","Isolated Surgical Aortic Valve Replacement in Low Risk AS Patients","the Prospective, Randomized, Controlled, Multi-center Study to Establish the Safety and Effectiveness of Isolated Surgical Aortic Valve Replacement in Low Risk Patients Who Have Symptomatic Severe Aortic Stenosis","AMETHYST","Inclusion Criteria:\n\n1. All study participants must meet the following inclusion criteria 1. Severe, calcific aortic stenosis with the following criteria:\n\n   * Jet velocity ≥4.0 m\u002Fs or mean gradient ≥ 40 mmHg OR\n   * AVA ≤1.0 cm2 or AVA index ≤ 0.6 cm2\u002Fm2 Note: Qualifying TTE must be within 90 days prior to randomization\n\n   AND 2. NYHA class ≥ II OR Exercisee test that demonstrates a limited exercise capacity, abnormal blood pressure response, or arrhythmia OR Asymptomatic patients with LVEF \\\u003C50%\n2. The Heart Team agrees that the surgical mortality risk is less than 4% according to STS-PROM. The Heart Team's assessment should include evaluation of overall clinical status and comorbidities that may not be adequately captured by risk calculators such as STS-PROM, in addition to the risk score itself.\n3. The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by certified review board.\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if any of the following conditions are present:\n\n1. History of cardiovascular surgery or thoracotomy\n2. Pre-existing other valvular disease, coronary artery disease or aortic disease required intervention Note: interventions for arrhythmia or root enlargement are not considered exclusionary.\n3. Heart Team assessment that chest abnormalities or significant frailty would prevent safe SAVR.\n4. Native aortic annulus size unsuitable for sizes the currently approved and marketed SAVR or TAVR based on preoperative 3D-CT image analysis.\n5. Iliofemoral vessel characteristics that whould preclude safe insertion of the introducer sheath.\n6. Evidence of an acute myocardial infarction or PCI ≤ 30 days before randomization\n7. Aortic valve is unicuspid\n8. Severe aortic regurgitation (\\>3+)\n9. Severe mitral regurgitation (\\>3+) or ≥ moderate stenosis\n10. Severe tricuspid regurgitation (\\>3+) or ≥ moderate stenosis\n11. Pre-existing mechanical or bioprosthetic valve in any position.\n12. Complex coronary artery disease:\n\n    1. Heart Team assessment that CABG is recommended at the time of SAVR\n    2. Heart Team assessment that optimal revascularization cannot be performed\n13. Symptomatic carotid or vertebral artery disease or treatment of carotid stenosis within 30 days of randomization\n14. Leukopenia (WBC \\\u003C 3000 cell\u002FmL), Thrombocytopenia (Plt \\\u003C 50,000 cell\u002FmL), history of bleeding diathesis or coagulopathy.\n15. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of randomization\n16. Hypertrophic cardiomyopathy with obstruction (HOCM)\n17. Ventricular dysfunction with LVEF \\\u003C 30%\n18. Cardiac imaging (echo, CT, and\u002For MRI) evidence of intracardiac mass, thrombus or vegetation\n19. Inability to tolerate or condition precluding treatment with antithrombotic\u002Fanticoagulation therapy during or after the valve implant procedure\n20. Stroke or transient ischemic attack (TIA) within 90 days of randomization\n21. Renal insufficiency (eGFR \\\u003C 30 ml\u002Fmin per the Cockcroft-Gault formula) and\u002For renal replacement therapy\n22. Active bacterial endocarditis within 180 days of randomization\n23. Severe lung disease (FEV1 \\\u003C 50% predicted) or currently on home oxygen\n24. Severe pulmonary hypertension (e.g., PA systolic pressure ≥ 2\u002F3 systemic pressure)\n25. History of cirrhosis or active liver disease\n26. Significant abdominal or thoracic aortic disease (such as porcelain aorta, aneurysm, severe calcification, aortic coarctation, etc.) that would preclude cannulation and aortotomy for SAVR or safe passage of the delivery system for TAVR.\n27. Patient refuses blood products.\n28. BMI \\> 50 kg\u002Fm2\n29. Estimated life expectancy \\\u003C 24 months.\n30. Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with pre-medication.\n31. Immobility or significant cognitive impairment that would prevent completion of study procedure.\n32. Currently participating in an investigational drug or another device study.\n33. Unsuitable as candidates by the principal investigator or a research associate for other reasons",{"count":54,"type":20},450,"INTERVENTIONAL",[57],"NA","To establish the safety and effectiveness of surgical aortic valve replacement (SAVR) in patients with isolated severe, calcific aortic stenosis who are at low surgical risk.",[60],"Aortic Stenosis","2026-09-03",{"date":63,"type":36},"2026-09-04",{"date":65,"type":36},"2025-06-01",{"date":67,"type":20},"2040-05-31",{"name":42,"class":43},37,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":55,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100511455","phase-2-a-multicenter-single-arm-p2-to-evaluate-safety-and-efficacy-of-the-total-neoadjuvant-therapy-for-ct2-rectal-cancer-100511455","NCT05939661","A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer","A Multicenter Single-arm Phase 2 Study to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy of Short Course Radiation Therapy Followed by Neoadjuvant Oxaliplatin\u002FFluorouracil-based Chemotherapy (CAPOX) for cT2 Rectal Cancer.","AMBITION","Inclusion Criteria:\n\n* 1\\. The patient has been fully informed of the contents of the study and has given written consent.\n\n  2\\. The patient has adenocarcinoma of the rectum confirmed by histological examination.\n\n  3\\. No distant metastases are detected on imaging studies, and radical resection is clinically feasible.\n\n  4\\. Age of 20 years or older on the date of consent. 5. ECOG Performance Status (PS) is 0 - 1 (PS 0 for age 71 years or older on the date of consent).\n\n  6\\. Previously untreated rectal cancer with the lower margin of the tumor within 12 cm of the anal verge (AV).\n\n  7\\. Patients with cT2N0M0 in the diagnosis before starting treatment (a lymph node with a short diameter of 7 mm or more is considered positive).\n\nThe conditions for lymph node metastasis shall be as follows. Contrast-enhanced CT or MRI (plain or contrast-enhanced) with a slice width of 5 mm or less.\n\n(i) Short diameter of 10 mm or more (ii) Short diameter of 7 mm or more and one or more of the following a) to c) are met\n\n(a) Edge irregularity (b) Low signal area with internal heterogeneity on MRI (c) Circular (long\u002Fshort diameter ratio \\\u003C 1.5) If contrast-enhanced CT is not possible due to contrast medium allergy, renal dysfunction, or bronchial asthma, simple CT is acceptable.\n\n8\\. The following criteria for major organ function within 14 days prior to registration are met.\n\nIf more than one test result exists within this period, the most recent one should be used. No blood transfusions or hematopoietic factor products should be administered within 14 days prior to the test date.\n\n1. Neutrophil count: greater than or equal to 1,500\u002Fmm3\n2. Platelet count: \\>= 10.0 x 104 \u002Fmm3\n3. Hemoglobin concentration: \\>=9.0 g\u002FdL\n4. Total bilirubin: 1.5 times or less than the upper limit of the institutional standard\n5. AST, ALT, ALP: 2.5 times or less than the upper limit of the institutional standard\n6. Serum creatinine: 1.5 times or less than the upper limit of the institutional standard or creatinine clearance: 45 mL\u002Fmin or more\n\nExclusion Criteria:\n\n* 1\\. underwent treatment by any of the following within a certain period of time prior to initiation of protocol therapy\n\n  1. extensive surgery (excluding CV port placement) within 4 weeks\n  2. Any anticancer therapy within 4 weeks\n  3. Radiation within 4 weeks 2. concomitant or pre-existing severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc.) 3. patients who have had a colonic stent implanted 4. patients with serious comorbidities (heart failure, renal failure, liver failure, bleeding peptic ulcer, intestinal paralysis, bowel obstruction, poorly controlled diabetes, etc.) 5. patients with active multiple overlapping cancers (synchronous multiple overlapping cancers or iatrogenic multiple overlapping cancers with a disease-free period of 5 years or less). However, carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma that is considered curable by local treatment is not considered active multiple overlapping carcinoma.\n\n     6\\. pregnant or lactating women, positive pregnancy test or unwillingness to use contraception 7. HBs antigen positive or HCV antibody positive. 8. has known human immunodeficiency virus (HIV) infection. 9. otherwise judged by the principal investigator or subinvestigator to be unsuitable for this study.","18 Years",{"count":80,"type":20},45,[82],"PHASE2","A multicenter single-arm phase 2 study to evaluate safety and efficacy of the total neoadjuvant therapy of short course radiation therapy followed by neoadjuvant oxaliplatin\u002Ffluorouracil-based chemotherapy (CAPOX) for cT2 rectal cancer",[85],"Rectal Cancer",[87,88,89,90,91,92,93],"total neoadjuvant therapy","neadjuvant chemotherapy","organ preservation","watch and wait","radiation","surgery","total mesorectum excision","2023-07-01",{"date":96,"type":36},"2023-07-11",{"date":98,"type":36},"2023-05-25",{"date":100,"type":20},"2030-03-31",{"name":42,"class":43},2,""]